Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials [0.03%]
与三联用药相比，蛋白酶抑制剂单药治疗更高的中枢神经系统不良反应风险？系统综述及随机对照试验结果分析
William Powderly,Andrew Hill,Christiane Moecklinghoff
William Powderly
Background: Protease inhibitor (PI) monotherapy for treatment could avoid the adverse events, drug resistance, and additional costs associated with other antiretrovirals that are normally used, particularly the nucleoside...
Aerobic fitness levels and validation of a non exercise VO2max prediction equation for HIV-infected patients on HAART [0.03%]
有氧运动能力和非锻炼预测HIV感染患者最大摄氧量的验证研究
Katherine Sullivan,Cecilia M Shikuma,Dominic Chow et al.
Katherine Sullivan et al.
Background: Non-exercise (N-EX) questionnaires have been developed to determine maximal oxygen consumption (VO2max) in healthy populations. There are limited reliable and validated N-EX questionnaires for the HIV+ populat...
Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening [0.03%]
单一快速试验在临床试验中筛查艾滋病毒(HIV)感染者失败原因分析
Estelle Piwowar-Manning,Jessica M Fogel,Oliver Laeyendecker et al.
Estelle Piwowar-Manning et al.
Background: In the HIV Prevention Trials Network (HPTN) 061 study, 8 (2.3%) of 348 HIV-infected participants identified as HIV uninfected at study enrollment using a single HIV rapid test for screening were found to be HI...
Clinical Trial
HIV clinical trials. 2014 Mar-Apr;15(2):62-8. DOI:10.1310/hct1502-62 2014
Switching to an etravirine-containing regimen due to drug intolerance in clinical practice [0.03%]
临床试验中因药物不耐受换用埃替拉韦方案治疗
L Martín-Carbonero,V Moreno,G Ramírez-Olivenza et al.
L Martín-Carbonero et al.
Background: Drug intolerance is one of the main reasons for switching antiretroviral therapy in HIV-infected patients. Etravirine (ETR) has demonstrated good tolerability in clinical trials and may be an option for patien...
Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data [0.03%]
将拉替拉韦联合富马酸替诺福韦二吡酯/恩曲他滨更换为捷诺维（艾维雷格/cobicistat/恩曲他滨/富马酸替诺福韦二吡酯）治疗病毒学上抑制的HIV-1感染者：48周数据
A Mills,G Crofoot,R Ortiz et al.
A Mills et al.
Background: Pill burden, dosing frequency, and concerns about safety and tolerability are important obstacles to maintaining adequate medication adherence. Raltegravir (RAL) is indicated for twice-daily dosing and when ta...
Clinical Trial
HIV clinical trials. 2014 Mar-Apr;15(2):51-6. DOI:10.1310/hct1502-51 2014
Phase I study demonstrates safety and tolerability of radiofrequency ablation (RFA) of the anal mucosa [0.03%]
第一期研究证明了射频消融(RFA)肛门黏膜的安全性和耐受性
A George Smulian,Diana M Moore,Jaime C Robertson et al.
A George Smulian et al.
Background: Anal carcinoma is increasing in high-risk populations. Dysplasia is often distributed throughout the anal mucosa, and focal ablative techniques have high rates of recurrence. ...
Clinical Trial
HIV clinical trials. 2014 Jan-Feb;15(1):36-44. DOI:10.1310/hct1501-36 2014
Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy [0.03%]
人类免疫缺陷病毒(HIV)基因型决定艾滋病母婴感染者人群的HIV嗜性及其抗逆转 transcriptomics-274
Antonio Di Biagio,Andrea Parisini,Bianca Bruzzone et al.
Antonio Di Biagio et al.
The aim of this study was to determine the coreceptor tropism by performing genotypic HIV-1 tropism testing in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy. Genotypic coreceptor tropism was dete...
Durability of the first antiretroviral treatment regimen and reasons for change in patients with HIV infection [0.03%]
HIV感染者初次抗逆转录病毒治疗方案的持久性及更换原因
Javier De La Torre-Lima,Ana Aguilar,Jesus Santos et al.
Javier De La Torre-Lima et al.
Background: To study the durability of the drugs and coformulations currently used in the first treatment regimen of antiretroviral therapy (ART) for HIV patients, and to examine the reasons for changing this medication. ...
Multicenter Study
HIV clinical trials. 2014 Jan-Feb;15(1):27-35. DOI:10.1310/hct1501-27 2014
Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials [0.03%]
尽管可以参与临床试验 但少数族裔在艾滋病研究中仍然代表性不足
Jose R Castillo-Mancilla,Susan E Cohn,Supriya Krishnan et al.
Jose R Castillo-Mancilla et al.
Background and objective: The reasons for minority underrepresentation in HIV/AIDS clinical trials remain unclear. We aimed to evaluate the knowledge, experience, and factors that influence minority participation in HIV/A...
Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients [0.03%]
无CCR5抑制的高效抗逆转录病毒治疗初治患者加用rosuvastatin降低炎症标志物较单用抗逆转录病毒药物更有效
Leonardo Calza,Elisa Vanino,Caterina Salvadori et al.
Leonardo Calza et al.
Objectives: Statins are lipid-lowering drugs that exhibit anti-Inflammatory and immune-modulatory properties, leading to a reduction of serum levels of C-reactive protein (CRP) in the general population. ...